3646 results for «654»
3646 results
Mitral interventions: procedural risk assessment and interventions
21 May 2026 – From EuroPCR 2026
Focused on mitral valve interventions, this session covers procedural risk assessment and outcomes following transcatheter edge-to-edge repair (TEER). Topics include predictive risk scores, technical complexity, pulmonary artery pressure indices, right ventricle-pulmonary artery coupling, and novel imaging predictors influencing procedural success and patient prognosis.
Inflammation and cardiovascular risk
21 May 2026 – From EuroPCR 2026
Exploring the interplay between inflammation and cardiovascular risk, this session reviews contemporary research on residual risk post-PCI, inflammatory markers in coronary artery disease especially in type 2 diabetes and ACS, and prognostic tools including lipoprotein(a) and systemic inflammation indices.
Modern risk prediction in TAVI
21 May 2026 – From EuroPCR 2026
This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.
The pearl of unloading with mechanical circulatory support
21 May 2026 – From EuroPCR 2026
Delve into the critical aspects of mechanical circulatory support in cardiogenic shock, focusing on device selection, assessment of persistent congestion, and the application of unloading tools to improve patient management and outcomes.
Haemodynamic support: from shock to complex high-risk interventional problems
21 May 2026 – From EuroPCR 2026
This session examines haemodynamic support from cardiogenic shock through to complex high-risk interventional cardiology procedures. It features registry data, clinical outcomes, and procedural techniques including mechanical circulatory support and arterial access strategies.
Which AF patients may benefit from LAA closure?
02 Jul 2026
Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.
Author
